Bank of America
FENC icon

Bank of America’s Fennec Pharmaceuticals FENC Stock Holding History

Bank of America’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162K Buy
26,405
+3,872
+17% +$29.9K ﹤0.01% 5422
2025
Q4 		$174K Buy
22,533
+9,090
+68% +$74.6K ﹤0.01% 5406
2025
Q3 		$126K Sell
13,443
-5,714
-30% -$49.5K ﹤0.01% 6500
2025
Q2 		$159K Sell
19,157
-3,248
-14% -$22.2K ﹤0.01% 6287
2025
Q1 		$136K Sell
22,405
-13,422
-37% -$86.2K ﹤0.01% 6352
2024
Q4 		$226K Buy
35,827
+8,703
+32% +$44.6K ﹤0.01% 6058
2024
Q3 		$136K Buy
27,124
+686
+3% +$3.97K ﹤0.01% 6199
2024
Q2 		$162K Buy
26,438
+9,959
+60% +$82.7K ﹤0.01% 6002
2024
Q1 		$183K Sell
16,479
-23,576
-59% -$237K ﹤0.01% 5926
2023
Q4 		$449K Buy
40,055
+8,318
+26% +$68.9K ﹤0.01% 5570
2023
Q3 		$238K Buy
31,737
+8,905
+39% +$72.5K ﹤0.01% 5795
2023
Q2 		$202K Buy
22,832
+16,097
+239% +$134K ﹤0.01% 5822
2023
Q1 		$56K Buy
6,735
+4,535
+206% +$42.1K ﹤0.01% 6467
2022
Q4 		$21.1K Sell
2,200
-420
-16% -$3.72K ﹤0.01% 6719
2022
Q3 		$21K Sell
2,620
-2,341
-47% -$16.1K ﹤0.01% 7011
2022
Q2 		$28K Hold
4,961
– – ﹤0.01% 7069
2022
Q1 		$28K Sell
4,961
-6,422
-56% -$32.4K ﹤0.01% 7390
2021
Q4 		$51K Buy
11,383
+6,536
+135% +$48.6K ﹤0.01% 7209
2021
Q3 		$45K Buy
4,847
+392
+9% +$2.94K ﹤0.01% 7097
2021
Q2 		$32K Sell
4,455
-29,152
-87% -$195K ﹤0.01% 6989
2021
Q1 		$209K Buy
33,607
+13,397
+66% +$101K ﹤0.01% 6000
2020
Q4 		$150K Sell
20,210
-493
-2% -$3.75K ﹤0.01% 5771
2020
Q3 		$125K Sell
20,703
-15,851
-43% -$112K ﹤0.01% 5565
2020
Q2 		$305K Buy
36,554
+27,882
+322% +$207K ﹤0.01% 4976
2020
Q1 		$52K Buy
+8,672
New +$56.6K ﹤0.01% 5857
2019
Q3 		– Sell
-9,098
Closed -$36K – 7317
2019
Q2 		$36K Buy
9,098
+6,663
+274% +$28.2K ﹤0.01% 6417
2019
Q1 		$11K Sell
2,435
-4,353
-64% -$28.6K ﹤0.01% 6625
2018
Q4 		$44K Buy
6,788
+4,560
+205% +$31.9K ﹤0.01% 6260
2018
Q3 		$19K Buy
2,228
+679
+44% +$6.3K ﹤0.01% 6518
2018
Q2 		$16K Sell
1,549
-9,583
-86% -$114K ﹤0.01% 6567
2018
Q1 		$135K Buy
+11,132
New +$105K ﹤0.01% 5582

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Bank of America's FENC Position: Q1 2026 in Review

Bank of America increased its Fennec Pharmaceuticals (FENC) stake by 17% in Q1 2026, buying an estimated $29.9K and bringing the position to 26,405 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #5422.

Bank of America first reported a position in FENC in Q1 2018 and has held it in 31 quarters since. The position peaked at $449K in Q4 2023. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Bank of America held 26,405 shares of Fennec Pharmaceuticals worth $162K as of Q1 2026.
  • Bank of America bought 3,872 Fennec Pharmaceuticals shares in Q1 2026, an estimated $29.9K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5422 holding.
  • Bank of America first reported a position in Fennec Pharmaceuticals in Q1 2018 and has held it in 31 quarters since.
  • Bank of America's Fennec Pharmaceuticals position peaked at $449K in Q4 2023.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.